News
RPTX
3.580
+6.87%
0.230
Weekly Report: what happened at RPTX last week (1028-1101)?
Weekly Report · 1d ago
Weekly Report: what happened at RPTX last week (1021-1025)?
Weekly Report · 10/28 09:17
Repare Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 10/24 19:25
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Benzinga · 10/24 19:16
Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes
TipRanks · 10/24 15:25
TD Cowen Sticks to Its Buy Rating for Repare Therapeutics (RPTX)
TipRanks · 10/24 11:41
Repare Therapeutics presents data from Phase 1 MYTHIC clinical trial
TipRanks · 10/23 10:16
Repare Therapeutics Presented Updated Data Highlighting The Benefits Of Its Individualized Schedule For Managing Anemia In Phase 1 MYTHIC Trial, Which Treated Patients With The Combination Of Lunresertib And Camonsertib
Benzinga · 10/23 10:07
REPARE THERAPEUTICS INC - ANALYSIS SHOWS SUCCESS IN MITIGATING ANEMIA, NO THROMBOCYTOPENIA
Reuters · 10/23 10:05
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Barchart · 10/23 05:05
Weekly Report: what happened at RPTX last week (1014-1018)?
Weekly Report · 10/21 09:18
Buy Rating Affirmed for Repare Therapeutics Amidst Promising Clinical Trials and Robust Financial Health
TipRanks · 10/14 12:35
Repare Therapeutics doses first patient in POLAR trial
TipRanks · 10/14 11:15
Repare Begins Clinical Trial Combining RP-3467 and PARP Inhibitor Olaparib to Fight Advanced Cancers
Benzinga · 10/14 11:06
REPARE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL OF RP-3467, A POLΘ ATPASE INHIBITOR
Reuters · 10/14 11:05
Weekly Report: what happened at RPTX last week (1007-1011)?
Weekly Report · 10/14 09:21
Weekly Report: what happened at RPTX last week (0930-1004)?
Weekly Report · 10/07 09:19
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise
Simply Wall St · 10/05 13:41
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Seeking Alpha · 10/04 18:02
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
TipRanks · 10/01 11:07
More
Webull provides a variety of real-time RPTX stock news. You can receive the latest news about Repare Therapeutics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.